Trial Profile
A Phase I Open Label Clinical Trial Evaluating the Safety and Efficacy of Adoptive Transfer of NY-ESO-1 TCR Engineered Autologous T Cells in Combination With Decitabine in Patients With Recurrent or Treatment Refractory Ovarian Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Mipetresgene autoleucel (Primary) ; Mipetresgene autoleucel (Primary) ; Aldesleukin; Cyclophosphamide
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 05 Jan 2021 Planned End Date changed from 8 Dec 2021 to 23 Mar 2032.
- 12 Jun 2020 Status changed from recruiting to active, no longer recruiting.
- 28 Feb 2020 Planned End Date changed from 15 Aug 2020 to 8 Dec 2021.